Fibromyalgia Pipeline Guide 2022: Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players –

Fibromyalgia Pipeline Guide 2022: Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players –

Fibromyalgia Pipeline Guide 2022: Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players –

DUBLIN–(BUSINESS WIRE)–The “Fibromyalgia (Fibromyalgia Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to’s offering.

The pipeline guide provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibromyalgia pipeline guide also reviews key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 10, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

The Fibromyalgia pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)

Key Topics Covered:

Therapeutics Development

  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Companies Involved in Therapeutics Development

  • Aardvark Therapeutics Inc
  • Aptinyx Inc
  • Cortene Inc
  • Engrail Therapeutics Inc
  • Epitech Group SpA
  • H. Lundbeck AS
  • Imbrium Therapeutics LP
  • Indaptus Therapeutics Inc
  • Luye Pharma Group Ltd
  • One World Cannabis Ltd
  • PRISM Pharma Co Ltd
  • Reven Holdings Inc
  • Shanghai Lvdao Pharmaceutical Technology Co Ltd
  • Statera Biopharma Inc
  • Tetra Bio-Pharma Inc
  • Teva Pharmaceutical Industries Ltd
  • Tonix Pharmaceuticals Holding Corp
  • Tryp Therapeutics Inc
  • Virios Therapeutics, Inc

Drug Profiles

Dormant Projects

Discontinued Products

Product Development Milestones

Featured News & Press Releases

For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900